Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76.

PMID:
15205914
2.

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM.

Clin Cancer Res. 2000 Aug;6(8):3071-80.

3.

Phase I trial of perillyl alcohol administered four times daily continuously.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2003 Nov;52(5):361-6.

PMID:
12904896
4.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

5.

Phase I clinical trial of perillyl alcohol administered daily.

Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH.

Clin Cancer Res. 1998 May;4(5):1159-64.

6.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.

Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA.

Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57.

PMID:
17885756
7.

Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.

da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass CR.

Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7. doi: 10.1016/j.surneu.2007.07.040.

PMID:
18295834
8.

A phase I trial of perillyl alcohol in patients with advanced solid tumors.

Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG.

Cancer Chemother Pharmacol. 2003 Jun;51(6):493-8.

PMID:
12695855
9.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

10.

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK.

Invest New Drugs. 2012 Feb;30(1):316-26. doi: 10.1007/s10637-010-9535-y.

PMID:
20839029
11.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G.

Invest New Drugs. 2003 Aug;21(3):367-72.

PMID:
14578686
12.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2157-66.

13.

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK.

J Clin Oncol. 2001 Jul 1;19(13):3267-79.

PMID:
11432895
14.

Phase I study of perillyl alcohol in patients with refractory malignancies.

Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A.

Cancer Biol Ther. 2002 Mar-Apr;1(2):130-5.

PMID:
12170772
15.

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.

Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.

Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82.

PMID:
16308697
16.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2001 Jul;7(7):1901-11.

17.

Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.

Zhang Z, Chen H, Chan KK, Budd T, Ganapathi R.

J Chromatogr B Biomed Sci Appl. 1999 May 14;728(1):85-95.

PMID:
10379660
18.

Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.

da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T.

Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):267-76. doi: 10.1007/s00005-008-0027-0.

19.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.

Clin Cancer Res. 1998 May;4(5):1153-8.

20.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM.

J Clin Oncol. 2002 Oct 1;20(19):4074-82.

PMID:
12351605
Items per page

Supplemental Content

Support Center